Cargando…
IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts
Glioblastoma (GBM) is a devastating cancer with basically no curative treatment. Even with aggressive treatment, the median survival is disappointing 14 months. Surgery remains the key treatment and the postoperative survival is determined by the extent of resection. Unfortunately, the invasive grow...
Autores principales: | Kurbegovic, Sorel, Juhl, Karina, Sørensen, Kasper Kildegaard, Leth, Julie, Willemoe, Gro Linno, Christensen, Anders, Adams, Yvonne, Jensen, Anja Ramstedt, von Buchwald, Christian, Skjøth-Rasmussen, Jane, Ploug, Michael, Jensen, Knud J., Kjaer, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210614/ https://www.ncbi.nlm.nih.gov/pubmed/34158842 http://dx.doi.org/10.7150/thno.49787 |
Ejemplares similares
-
Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
por: Gao, Rebecca W., et al.
Publicado: (2018) -
Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW
por: Amini, Abolfazl, et al.
Publicado: (2022) -
Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats
por: Marshall, Milton V., et al.
Publicado: (2010) -
Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
por: Bernhard, Wendy, et al.
Publicado: (2021) -
Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets
por: Cohen, Ruth, et al.
Publicado: (2011)